Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Keytruda (pembrolizumab) - Merck (MSD)
Kiosk 6 (AVAHO 2026) - Oct 11, 2026 - Pres time: Sep 12, 2026; 11:15 AM - 12:15 PM; "40-Reducing Consult View-Alert Burden in VA Oncology Through Consult Tracking Manager Implementation 41-Reducing Infusion Wait Times: Enhancing Veteran Care at the VA NJ Healthcare System 42-Safety and Feasibility of Accelerated Pembrolizumab and Nivolumab Infusions: A Quality Improvement Initiative 43-Syngeneic modeling of Western diet in the generation of hepatocellular carcinoma 44-The future of Oncology Clinical Pathways within the Veterans Health Administration 45-Update of real-world testing for Duffy-Null Associated Neutrophil Count prior to hematology consult 46-Predicting Prostate Cancer Mortality using Deep Learning incorporating different Comorbidity indices" 
Genito-urinary Cancer • Hepatocellular Cancer • Prostate Cancer • Solid Tumor
https://www.avaho.org/the-annual-meeting/agenda/
 
Shiyi Pang
 
Oct 11, 2026
 
Prev Next